BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$50.01M, compared with -$23.57M a year earlier.
Context
- Net debt amounted to 12.0% of total assets at the end of Q1 FY2026, down 3.8 pp from a year earlier.
- Net debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -112.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (370.92M) USD
- Year-over-year change
- -21747.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (370.92M) | -21747.5% |
| FY2024 | 2024-12-31 | (1.7M) | -2522.1% |
| FY2023 | 2023-12-31 | 70.1K | +62.6% |
| FY2022 | 2022-12-31 | 43.11K | +16.6% |
| FY2021 | 2021-12-31 | 36.96K | — |
Net Debt vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -112.2% is the 8th highest of 10, against a peer median of -5.7%.
- Net debt amounts to 12.0% of total assets for BBOT, versus a peer median of 23.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.8M USD | +310.2% | -26.2% | 33.8% | |
| Sep 2026 | $57.89M USD | +688.5% | — | 27.6% | |
| Mar 2026 | $28.89M USD | +134.8% | — | 8.8% | |
| Jun 2026 | $20.55M USD | -12.5% | +186.4% | 2.8% | |
| Mar 2026 | -$14.6M USD | -104.1% | — | 4.8% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | -$50.01M USD | -112.2% | — | 12.0% |
| Sep 2026 | -$55.66M USD | -136.1% | — | 5.4% | |
| Mar 2026 | -CHF 62.13M CHF | -5.7% | — | 25.5% | |
SEPNSepterna, Inc. | Sep 2026 | -$145.13M USD | +50.9% | — | 23.4% |
| Aug 2026 | -$654.91M USD | -2883.4% | — | 54.8% | |
| Peer median (excluding BBOT) | — | -5.7% | +80.1% | 23.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.